Osteoactivin is overexpressed in aggressively bone metastatic 4T1 subpopulations versus weakly bone metastatic breast cancer populations. Osteoactivin.

Slides:

Advertisements

Similar presentations

PIK3CA gene amplification in glioblastoma and squamous cell carcinoma (SCC) of the lung. PIK3CA gene amplification in glioblastoma and squamous cell carcinoma.

Advertisements

PP1 and PP2A inhibitors rescue α-SMA expression and Akt phosphorylation from the inhibitory effects of TSA. After serum starvation, NHLFs were pretreated.

HMGA2 is a SUMOylation target.

IL-1β stimulates CXCL5 and CXCL8 gene expression and protein secretion in A549 cells in a time- and dose-dependent manner. IL-1β stimulates CXCL5 and CXCL8.

Van’t Veer et al, Nature 415: (2002)

25(OH)D and 1,25(OH)2D perfusion treatment effect on cancer-related markers: IF stains illustrating expression levels for Ki-67 (A), cyclin D1 (B), ErbB-2.

Microarray analysis of phospho-Twist1–responsive genes.

Volume 22, Issue 4, Pages (October 2015)

Increase in beige/brown adipocyte characteristics in the xenografts from additional breast cancer cell lines. Increase in beige/brown adipocyte characteristics.

Expression changes of specific epigenetic-controlled tumor-related genes by the prenatal/maternal BSp treatment. qRT-PCR and Western blot analysis were.

Appearance of prominin-1-containing membrane particles in the culture medium upon differentiation of Caco-2 cells. Appearance of prominin-1-containing.

Knocking down Wnt3 increases the cells' response to trastuzumab and reduces cells' invasiveness. Knocking down Wnt3 increases the cells' response to trastuzumab.

ONC201 activates the ISR. ONC201 activates the ISR. (A) Western blotting analysis for ATF4, CHOP, ATF3, and TRB3 on lysates from HCT116 cells cultured.

α-Cells mainly express SSTR2 and SSTR3

IL-6 inhibits insulin-induced formation of p85/IRS-1 complexes.

The p53 pathway is involved in the inhibition of cell proliferation observed in 15-LOX-1-overexpressing cells. The p53 pathway is involved in the inhibition.

(A) Relative expression levels of the top most down-regulated genes in LATS2L breast tumors (TCGA-BRCA dataset, see Fig 1) in the panel of breast cancer.

Protection from 4T1 tumor rechallenge in treated mice.

co-IP of LEDGF/p75 and MeCP2.

Aberrant regulation of HDAC2 and its association with malignant proliferation of human gastric cancer. Aberrant regulation of HDAC2 and its association.

PTB-independent ShcA pools require Src to promote mammary tumorigenesis. PTB-independent ShcA pools require Src to promote mammary tumorigenesis. A, Src.

Expression analysis of IGFBP-3 using human whole-genome microarray.

Representative Western blot analyses of S-phase and other proteins from PC3 cell lysates obtained 3 days after oligomer (400 nm)/Lipofectin (15 μg/ml)

Variation in dUTPase expression in cell lines.

Protein expression profile in a dasatinib-resistant cell line.

IL6 mRNA is not detected in metastatic prostate cancer cells.

Imatinib mesylate inhibits PDGF-mediated ERK and Akt activation.

Reduced BAI1 expression is associated with breast cancer patient survival. Reduced BAI1 expression is associated with breast cancer patient survival. A,

ALDH1A3 is mainly responsible for the ALDH activity in two human cholangiocarcinoma lines. ALDH1A3 is mainly responsible for the ALDH activity in two human.

A, GP and GR epithelial tumor cells are equally responsive to gefitinib. A, GP and GR epithelial tumor cells are equally responsive to gefitinib. Equal.

Expression of versican in mammary tumor stem/progenitor cells.

AXL is not expressed in human prostate tumors.

Down-regulation of the erbB-2 receptor by trastuzumab decreases Akt kinase activation but not MAPK activation. Down-regulation of the erbB-2 receptor by.

Matriptase-2 inhibited breast tumor development in vivo.

Ki-67 expression is determined by the cell-cycle stage.

VEGF expression in neoplastic and normal prostate tissue.

Overexpression of L1 in CRC cells induces NF-κB activation and suppression of p65 expression blocks the capacity to confer liver metastasis. Overexpression.

Expression of CRC stem cell markers and L1 in CRC cells.

Overexpression of DDB2 reduces invasive abilities in lungs of aggressive breast tumor cells. Overexpression of DDB2 reduces invasive abilities in lungs.

sir2α null cells differentiate in vitro.

PKM2 activation was suppressed by overexpression of MnSOD during early skin carcinogenesis. PKM2 activation was suppressed by overexpression of MnSOD during.

Fyn cooperates with Src to increase the tumorigenic potential of PTB-independent ShcA signaling complexes. Fyn cooperates with Src to increase the tumorigenic.

In vivo tumorigenicity of MKN-1 cells with sustained suppression of HDAC2. In vivo tumorigenicity of MKN-1 cells with sustained suppression of HDAC2. A,

Paclitaxel treatment along with CXCR2 knockdown reduces tumor growth and metastasis. Paclitaxel treatment along with CXCR2 knockdown reduces tumor growth.

Microarray analysis of global gene expression profiles of PC-3 and derivative cell lines. Microarray analysis of global gene expression profiles of PC-3.

PTB-independent ShcA pools employ distinct domains to hyperactivate mTOR and Src signaling. PTB-independent ShcA pools employ distinct domains to hyperactivate.

PTB-independent ShcA pools require a functional SH2 domain, but not the tyrosine phosphorylation sites to promote mammary tumorigenesis. PTB-independent.

Northern blot analysis of maspin in cancer cell lines and human tissues. Northern blot analysis of maspin in cancer cell lines and human tissues. A, HMECs.

SBC-5 miR-335+, but not SBC-5 miR-29a+, exhibited reduced IGF-IR expression. SBC-5 miR-335+, but not SBC-5 miR-29a+, exhibited reduced IGF-IR expression.

Effects of HDAC2 inactivation on the invasive potential of human gastric cancer cells. Effects of HDAC2 inactivation on the invasive potential of human.

Changes in signal transduction pathway induced by gefitinib.

Increased levels of acetylated histone H3 are observed in normal PBMCs and circulating tumor cells obtained from patients post-depsipeptide treatment.

Expression of versican promoted breast cancer cell tumor formation and self-renewal in vivo. Expression of versican promoted breast cancer cell tumor formation.

Met is expressed in Her2-overexpressing cell lines and Her2 (+) breast tumors. Met is expressed in Her2-overexpressing cell lines and Her2 (+) breast tumors.

Representative images demonstrating LOH in breast cancer patients’ paired BM aspirate and primary tumors (T) at D14S62, D14S51, and D8S321, respectively.

Activation of multiple RTKs in chondrosarcoma cells.

Osteoactivin expression is required for the invasive phenotype of in vivo selected bone metastatic 4T1 breast cancer cells. Osteoactivin expression is.

ODC protein expression in paired benign and cancer tissue obtained from patients with PCA. The protein expression was measured by immunoblot analysis in.

Enhanced expression of Cap43 gene by nickel in breast cancer cell lines. Enhanced expression of Cap43 gene by nickel in breast cancer cell lines. Expression.

Expression of HIF-1α and β-catenin in hypoxic HCC cell lines and HAL-treated xenografts. Expression of HIF-1α and β-catenin in hypoxic HCC cell lines and.

SPARC is required for spontaneous metastasis

SAHA blocks IR-induced increase of RAD51 protein in MM cells.

Proliferation of TA3-Ha and TA3-St cells in vitro and in vivo.

P53 restoration in a syngeneic transplant model of Mdm2Tg p53Neo/Neo CreER angiosarcoma. p53 restoration in a syngeneic transplant model of Mdm2Tg p53Neo/Neo.

Tumor-suppressor Lkb1 inactivation promotes neutrophil accumulation via proinflammatory cytokines and chemokines. Tumor-suppressor Lkb1 inactivation promotes.

Venn diagram showing the overlap of PD-L1 overexpression, MSI-NGS–high, and TML-high in all gastrointestinal tumors, with all three markers tested (N =

Detection of microcalcifications in 4T1 mammary tumors and human breast tumor tissue. Detection of microcalcifications in 4T1 mammary tumors and human.

T3 or T4 induces MAPK activation in myeloma cells.

Fig. 3 Minimal treatment of ETL decreases metastatic burden and prolongs survival in the 4T1 breast carcinoma model after tumor resection. Minimal treatment.

Overexpression of SUFU and GLI1 in the poor clinical outcome subgroup was confirmed by real-time PCR along with its association with disease progression.

Presentation transcript:

Osteoactivin is overexpressed in aggressively bone metastatic 4T1 subpopulations versus weakly bone metastatic breast cancer populations. Osteoactivin is overexpressed in aggressively bone metastatic 4T1 subpopulations versus weakly bone metastatic breast cancer populations. A. The relative expression of osteoactivin (Agilent whole mouse genome microarray), expressed as the fold change relative to the parental 4T1 population. B. Northern blot analysis of in vivo selected, aggressively bone metastatic 4T1 subpopulations probed with osteoactivin and GAPDH as a loading control. Quantitative phosphorimager analysis was done and the values for osteoactivin were first normalized to GAPDH and then expressed relative to the 4T1 parental population. C. Immunoblot analysis of osteoactivin expression in weakly and aggressively bone metastatic breast cancer populations in culture. D. Immunoblot analysis of osteoactivin expression in primary tumor explants arising from mammary fat pad injection of parental 4T1 cells. Lysates from cultured 4T1 (4T1p) and bone metastatic (592 BM2) cells are included as negative and positive controls, respectively. The membranes in C and D were probed for α-tubulin as a loading control. April A.N. Rose et al. Mol Cancer Res 2007;5:1001-1014 ©2007 by American Association for Cancer Research